Navigation Links
Third Circuit Rules in Mylan's Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylan's Breach of Contract Claim Against GSK to Trial
Date:7/23/2013

PITTSBURGH, July 23, 2013 /PRNewswire/ -- Mylan Inc. (NASDAQ: MYL) today announced that the Third Circuit Court of Appeals has reversed a summary judgment ruling dismissing Mylan's claim for breach of contract against GlaxoSmithKline relating to Paroxetine Hydrochloride Extended-release (ER) Tablets. The court ordered that Mylan's contract claim proceed to trial in U.S. District Court for the District of New Jersey. Mylan had filed suit against GSK claiming that GSK's agreement to supply Apotex with Paroxetine Hydrochloride ER violated Mylan's settlement and license agreement with GSK.  Mylan is seeking money damages and an order permanently enjoining GSK from supplying Apotex with Paroxetine Hydrochloride ER. The company is pleased with the court's decision and the case will proceed to trial.

This press release includes statements that constitute "forward-looking statements," including with regard to litigation and sales of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Announces Third Quarter 2013 Earnings Conference Call Tuesday, July 30, 2013
2. Hill-Rom Announces Preliminary Fiscal 2013 Third Quarter Results and Search for New CFO; Adjusted Earnings Per Share Expected to be in Line with Guidance
3. Span-America Medical Systems to Release Third Quarter Results on July 31, 2013
4. Aviir Secures Third $10 Million Financing Tranche To Fund Expanded Sales Of New Heart Risk Test
5. New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples
6. Lilly Declares Third-Quarter 2013 Dividend
7. Cantel Medical Reports EPS of $0.33 vs. $0.30 on 8% Sales Increase for Third Quarter Ended April 30, 2013
8. Cantel Medical Corp. To Hold Conference Call To Discuss Results for Its Third Quarter Ended April 30, 2013
9. Hill-Rom Increases Third Quarter 2013 Dividend
10. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
11. TPI Reports Third Quarter Fiscal Year 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Extremity Braces & Support) is Expected to Gain a Significant ... Prone to Orthopedic Ailments  ... , , According ... Market Study on Medical Implants Sterile Packaging: Clamshell Product Type ...
(Date:12/2/2016)... 2016   CytoSorbents Corporation (NASDAQ: CTSO ... Union approved CytoSorb ® cytokine adsorber to treat ... announced that Dr. Phillip Chan , Chief Executive ... Micro Main Event investor conference held from December ... Sunset Boulevard Hotel in Los Angeles, California ...
(Date:12/2/2016)... , December 2, 2016 On Thursday, ... 1.36%; the Dow Jones Industrial Average edged 0.36% higher, to ... down 0.35%. Losses were broad based as six out of ... initiated research reports on the following Services equities: Myriad Genetics ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a ... applications, was named the best Sales Team of 2016 as part of the ... today by the Software & Information Industry Association (SIIA), the principal trade association ...
(Date:11/30/2016)... Boston, Massachusetts (PRWEB) , ... November 30, 2016 ... ... is proud to announce that we have been designated as a Cigna Infertility ... meet or exceed rigorous performance standards. , “It’s an honor to be ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... workers have been a focus of public policymakers and system stakeholders in many ... (WCRI) released its Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) ...
Breaking Medicine News(10 mins):